EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST
Pexels / Pixabay

EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST

  Recently, Blueprint Medicines Corporation ("Blueprint") shared that the European Commission (EC) approved marketing authorization of AYVAKYT (avapritinib). The therapy is designed to treat adult patients with PDGFRA D842V mutated gastrointestinal stromal…

Continue Reading EC Approves Marketing Authorization of AYVAKYT for Patients with PDGFRA D842V Mutant GIST
Study: QINLOCK as a Treatment for Gastrointestinal Stromal Tumors
source: pixabay.com

Study: QINLOCK as a Treatment for Gastrointestinal Stromal Tumors

According to an article from BioTech 365, data from the Phase 3 INVICTUS trial and Phase 1 dose-escalation study, which evaluated QINLOCK as a treatment for gastrointestinal stromal tumors, was…

Continue Reading Study: QINLOCK as a Treatment for Gastrointestinal Stromal Tumors
Phase 1 QINLOCK Results for Patients with GIST Now Published
Source: pixabay.com

Phase 1 QINLOCK Results for Patients with GIST Now Published

Last week, biopharmaceutical company Deciphera Pharmaceuticals announced results from its Phase 1 clinical trial on QINLOCK (ripretinib). The study, published in the Journal of Clinical Oncology, tested QINLOCK as a potential…

Continue Reading Phase 1 QINLOCK Results for Patients with GIST Now Published
Ripretinib for GIST Receives Priority Review Status in China
mohamed_hassan / Pixabay

Ripretinib for GIST Receives Priority Review Status in China

  According to ONCLive, ripretinib, designed to treat patients with advanced gastrointestinal stroll tumors (GIST), was given Priority Review status in China by the National Medical Products Administration. This status…

Continue Reading Ripretinib for GIST Receives Priority Review Status in China
July 13th is GIST Awareness Day: Spreading Rare Disease Awareness
source: pixabay,com

July 13th is GIST Awareness Day: Spreading Rare Disease Awareness

Each year, June 13th is celebrated as Gastrointestinal Stromal Tumors (GIST) Awareness Day. The ultimate goal of awareness days for rare diseases is to help inform both the general public…

Continue Reading July 13th is GIST Awareness Day: Spreading Rare Disease Awareness
New Treatment Approved in Canada for Gastrointestinal Stromal Tumor
source: pixabay.com

New Treatment Approved in Canada for Gastrointestinal Stromal Tumor

According to a story from Biotech 365, the biopharmaceutical company Deciphera Pharmaceuticals has recently announced that the company's drug ripretinib (marketed as QINLOCK™) has been approved by Health Canada. The…

Continue Reading New Treatment Approved in Canada for Gastrointestinal Stromal Tumor
FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients
source: pixabay.com

FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients

  Surgery has been found to often be the best option towards a cure for a cancerous tumor (resectable) but there are many other tumors that are diagnosed as unresectable…

Continue Reading FDA’s Acceptance of AYVAKIT’s New Drug Application Offers Hope to Metastatic GIST Patients
FDA Approves a New Treatment for Gastrointestinal Stromal Tumors
source: pixabay.com

FDA Approves a New Treatment for Gastrointestinal Stromal Tumors

According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved avapritinib (marketed as AYVAKIT) as a treatment for gastrointestinal stromal tumors in cases when…

Continue Reading FDA Approves a New Treatment for Gastrointestinal Stromal Tumors

Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug

According to a story from BioPortfolio, the biopharmaceutical company Deciphera Pharmaceuticals, Inc., recently announced the release of preliminary data from the company's Phase I clinical trial, which is still in…

Continue Reading Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug
#ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
Source: Pixabay.com

#ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness

July 13th was Gastrointestinal Stromal Tumors Awareness Day! And that "13" has extra relevance. 5,000 Americans are diagnosed with Gastrointestinal Stromal Tumors (GIST) each year. That’s 13 people diagnosed each…

Continue Reading #ICYMI: Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
source: pixabay.com

Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness

July 13th is Gastrointestinal Stromal Tumors Awareness Day! And that "13" has extra relevance. 5,000 Americans are diagnosed with Gastrointestinal Stromal Tumors (GIST) each year. That’s 13 people diagnosed each day.…

Continue Reading Join the Rare 13 Campaign for Gastrointestinal Stromal Tumors Awareness
Close Menu